Taking people in FrancePhase 2/3
Long-term follow-up of people treated with NTLA-2001 for transthyretin amyloidosis
Follows adults who received NTLA-2001 earlier, to observe its long-term effects.
Plain-language title generated from the registry record
Registry title: Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001
Key facts
- Where
- Le Kremlin-Bicetre, FranceSee the site
- Phase
- Phase 2/3
Where in France
- Assistance Publique Hopitaux De ParisLe Kremlin-Bicetre, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Intellia Therapeutics
- Trial code
- NCT05697861EU 2023-507385-11-00
- Record updated
- 3 August 2026
- Original description
This is a follow-up study of subjects who received NTLA-2001 in a previous clinical trial as an observational evaluation of the long-term effects of the investigational therapy.Read full original descriptionShow less
Long-Term Follow-Up of Subjects Treated With NTLA-2001
This is a follow-up study of subjects who received NTLA-2001 in a previous clinical trial as an observational evaluation of the long-term effects of the investigational therapy.
Inclusion: A subject has completed or discontinued from an Intellia-sponsored clinical study in which a complete or partial dose of NTLA-2001 was received; A subject has provided informed consent for the LTFU study.
Exclusion: None.